📰 Athersys Inc News
Page 5 - Athersys Inc News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Athersys Inc. Real-time updates on events, politics, business and more.
October 10, 2023
The MOU includes $1.5M to $4.5M near term payments plus up to $150M in milestones ...
October 10, 2023
U.S. stocks traded higher toward the end of trading, with the Dow Jones gaining around 175 points on Tuesday. The Dow traded up 0.53% to 33,781.59 while the NASDAQ rose 0.72% to 13,581.64. The S&P 500 also rose, gaining, 0.68% to 4,364.93.
October 10, 2023
U.S. stocks traded higher midway through trading, with the Dow Jones gaining over 250 points on Tuesday. The Dow traded up 0.81% to 33,876.62 while the NASDAQ rose 1.23% to 13,650.54. The S&P 500 also rose, gaining, 1.10% to 4,383.17.
October 4, 2023
CLEVELAND & LEXINGTON, Ky.--(BUSINESS WIRE)--Athersys, Inc. (Nasdaq: ATHX), a cell therapy and regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, and Multipotent Adult Progenitor Cell (MAPC®) technology for equine, canine, and feline health applications, announces the...
October 4, 2023
/PRNewswire/ -- The cell therapy market size is expected to grow by USD 31.04 billion from 2022 to 2027. In addition, the momentum of the market will progress...
October 4, 2023
The cell therapy market size is expected to grow by USD 31.04 billion from 2022 to 2027. In addition, the momentum of the market will progress at a CAGR of 57.06% during the forecast period, according to Technavio Research. The market has been segmented by type (autologous and allogenic), application (malignancies, musculoskeletal, cardiovascular, and others), and geography (North America, Europe, Asia, and the Rest of the World (ROW)). North America accounts for 40% of the growth of the global
October 3, 2023
CLEVELAND--(BUSINESS WIRE)--Athersys, Inc. (Nasdaq: ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announces changes to its Board of Directors following the Company’s recent 2023 Annual Meeting of Stockholders. Current Director Jane Wasman, JD, has been ap...
October 2, 2023
Athersys, Inc. , a regenerative medicine company developing MultiStem® for critical care indications, announces changes to its Board of Directors following the Company’s recent 2023 Annual...
September 20, 2023
StockNews.com began coverage on shares of Athersys (NASDAQ:ATHX – Free Report) in a report published on Sunday morning. The firm issued a hold rating on the biopharmaceutical company’s stock. Athersys Price Performance Shares of Athersys stock opened at $0.31 on Friday. Athersys has a one year low of $0.26 and a one year high of […]